Previous 10 | Next 10 |
The following slide deck was published by Arbutus Biopharma Corporation in conjunction with this Read more ...
Arbutus Biopharma ( ABUS -28% ) plummets to multi-year lows after discontinuing development of its AB-506 oral capsid inhibitor for the treatment of chronic hepatitis B after two normal healthy volunteers in a clinical trial developed cases of acute hepatitis. More news on: Arbutus Bio...
Arbutus Biopharma (NASDAQ: ABUS ) -25% after a decision to stop development of AB-506. More news on: Arbutus Biopharma Corporation, Ovid Therapeutics Inc., PDS Biotechnology Corporation, Stocks on the move, Read more ...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify (click the highlighted links). All eyes will be on the September jobs report as investors look for clues on whether the Federal Res...
Arbutus Biopharma (NASDAQ: ABUS ) has tanked after hours, falling 24.5% after a decision to stop development of AB-506 . More news on: Arbutus Biopharma Corporation, Healthcare stocks news, Stocks on the move, Read more ...
WARMINSTER, Pa., Oct. 03, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a Hepatitis B Virus (HBV) therapeutic solutions company, today announced its decision to discontinue the clinical development of AB-506, an oral capsid inhibitor. AB-506 was in a Phase 1a/1...
Quick Take Vir Biotechnology ( VIR ) has filed to raise $150 million from the sale of its common stock, per an S-1/A registration statement . The company is advancing an ambitious pipeline of drug and antibody treatments for immune system and infectious diseases. VIR has produced intrig...
WARMINSTER, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that the Company will be participating in the following investor conferences in October 2019: Cant...
Quick Take Vir Biotechnology ( VIR ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an S-1 registration statement . The firm is developing therapeutics for serious immune system and infectious diseases. VIR is using Alnylam’s siRNA technology plat...
WARMINSTER, Pa., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Andrew Cheng, M.D., Ph.D., has been appointed to the Arbutus Board of Directors effective August 1...
News, Short Squeeze, Breakout and More Instantly...
Arbutus Biopharma Corporation Company Name:
ABUS Stock Symbol:
NASDAQ Market:
Arbutus Biopharma Corporation Website:
WARMINSTER, Pa., July 18, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that it ...
Data highlighted in oral presentation at the European Association for the Study of the Liver (EASL) Congress WARMISTER, Pa., June 06, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS) (“Arbutus” or the “Company”), a clinical-stage biopharmac...
In t he HBV003 trial, 67% of participants had HBsAg <10 IU/mL and 19% of participants had undetectable HBsAg when assessed for NUC discontinuation (end of treatment) or later, and 76% of participants were eligible for nucleos(t)ide analogue (NUC) therapy discontinuation. In the...